Treatment of sentinel node-positive breast cancer

Expert Review of Anticancer Therapy

Volumn 6, Issue 8, 2006, Pages 1233-1239

  Chagpar, Anees B ^a   McMasters, Kelly M ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Axillary dissection; Breast cancer; Micrometastasis; Sentinel node; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; EOSIN; HEMATOXYLIN;

ACCURACY; ARM EDEMA; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTECTOMY; MEDICAL DECISION MAKING; MORBIDITY; PARESTHESIA; PATIENT COUNSELING; PATIENT SELECTION; POLYMERASE CHAIN REACTION; POSTOPERATIVE PAIN; PROGNOSIS; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SENTINEL LYMPH NODE BIOPSY; TREATMENT REFUSAL; TUMOR VOLUME;

BIOPSY; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; LYMPH NODE EXCISION; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; SENTINEL LYMPH NODE BIOPSY;

EID: 33748123979     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.8.1233     Document Type: Review

References (59)

1. Neville AM, Price KN, Gelber RD, Goldhirsch A. Axillary node micrometastases and breast cancer. Lancet 337, 1110 (1991).
2. Cote RJ, Peterson HF, Chaiwun B et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 354, 896-900 (1999).
3. Cserni G, Amendoeira I, Apostolikas N et al. Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. J. Clin. Pathol. 57, 695-701 (2004).
4. White RL Jr, Wilke LG. Update on the NSABP and ACOSOG breast cancer sentinel node trials. Am. Surg. 70, 420-424 (2004).
5. Singletary SE, Allred C, Ashley P et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J. Clin. Oncol. 20, 3628-3636 (2002).
6. Cserni G, Gregori D, Merletti F et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br. J. Surg. 91, 1245-1252 (2004).
7. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N. Engl. J. Med. 347, 567-575 (2002).
8. Carlson RW, Brown E, Burstein HJ et al. NCCN Task Force Report: adjuvant therapy for breast cancer. J. Natl. Compr. Canc. Netw. 4(Suppl. 1), S1-S26 (2006).
9. Recht A, Edge SB, Solin LJ et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 19, 1539-1569 (2001).
10. Harris JR, Halpin-Murphy P, McNeese M, Mendenhall NP, Morrow M, Robert NJ. Consensus statement on postmastectomy radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 44, 989-990 (1999).
11. Barranger E, Dubernard G, Fleurence J, Antoine M, Darai E, Uzan S. Subjective morbidity and quality of life after sentinel node biopsy and axillary lymph node dissection for breast cancer. J. Surg. Oncol. 92, 17-22 (2005).
12. Peintinger F, Reitsamer R, Stransl H, Ralph G. Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. Br. J. Cancer 89, 648-652 (2003).
13. Van Zee KJ, Manasseh DM, Bevilacqua JL et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg. Oncol. 10, 1140-1151 (2003).
14. Lambert LA, Ayers GD, Hwang RF et al. Validation of a breast cancer nomogram for predicting nonsentinel lymp node matastases after a positive sentinel node biopsy. Ann. Surg. Oncol. 13, 310-320 (2006).
15. Smidt ML, Kuster DM, van der Wilt GJ, Thunnissen FB, Van Zee KJ, Strobbe LJ. Can the Memorial Sloan-Kettering Cancer Center nomogram predict the likelihood of nonsetinel lymph node metastases in breast cancer patients in The Netherlands? Ann. Surg. Oncol. 12, 1066-1072 (2005).
16. Degnim AC, Reynolds C, Pantvaidya G et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am. J. Surg. 190, 543-550 (2005).
17. Kocsis L, Svebis M, Boross G et al. Use and limitations of a nomogram predicting the likelihood of non-sentinel node involvement after a positive sentinel node biopsy in breast cancer patients. Am. Surg. 70, 1019-1024 (2004).
18. Soni NK, Carmalt HL, Gillett DJ, Spillane AJ. Evaluation of a breast cancer nomogram for prediction of nonsentinel lymph node positivity. Eur. J. Surg. Oncol. 31, 958-964 (2005).
19. Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann. Surg. Oncol. 12, 654-659 (2005).
20. Barranger E, Coutant C, Flahault A, Delpech Y, Darai E, Uzan S. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res. Treat. 91, 113-119 (2005).
21. Chagpar A, Scoggins CR, Martin RC et al. Prediction of sentinel lymph node-only disease in women with invasive breast cancer. Am. J. Surg. (2006) (In Press).
22. Leidenius MH, Vironen JH, Riihela MS et al. The prevalence of non-sentinel node metastases in breast cancer patients with sentinel node micrometastases. Eur. J. Surg. Oncol. 31, 13-18 (2005).
23. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer 73, 664-667 (1994).
24. Mignotte H, Treilleux I, Faure C, Nessah K, Bremond A. Axillary lymph-node dissection for positive sentinel nodes in breast cancer patients. Eur. J. Surg. Oncol. 28, 623-626 (2002).
25. Travagli JP, Atallah D, Mathieu MC et al. Sentinel lymphadenectomy without systematic axillary dissection in breast cancer patients: predictors of non-sentinel lymph node metastasis. Eur. J. Surg. Oncol. 29, 403-406 (2003).
26. Katz A, Niemierko A, Gage I et al. Factors associated with involvement of four or more axillary nodes for sentinel lymp node-positive patients. Int. J. Radiat. Oncol. Biol. Phys. 65, 40-44 (2006).
27. Shahar KH, Hunt KK, Thames HD et al. Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation field. Int. J. Radiat. Oncol. Biol. Phys. 59, 1074-1079 (2004).
28. Rivers AK, Griffith KA, Hunt KK et al. Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. Ann. Surg. Oncol. 13, 36-44 (2006).
29. Chagpar A, Scoggins CR, Martin RC et al. Predicting patients at low probability of requiring post-mastectomy radiation therapy. Ann. Surg. Oncol. (2006) (In Press).
30. Mullenix PS, Brown TA, Meyers MO et al. The association of cytokeratin-only-positive sentinel lymph nodes and subsequent metastases in breast cancer. Am. J. Surg. 189, 606-609 (2005).
31. Inokuchi M, Ninomiya I, Tsugawa K, Terada I, Miwa K. Quantitative evaluation of metastases in axillary lymph nodes of breast cancer. Br. J. Cancer 89, 1750-1756 (2003).
32. Wong SL, Chao C, Edwards MJ, Simpson D, McMasters KM. The use of cytokeratin staining in sentinel lymph node biopsy for breast cancer. Am. J. Surg. 182, 330-334 (2001).
33. Pendas S, Dauway E, Cox CE et al. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients. Am. Surg. 65, 500-505 (1999).
34. Schreiber RH, Pendas S, Ku NN et al. Microstaging of breast cancer patients using cytokeratin staining of the sentinel lymph node. Ann. Surg. Oncol. 6, 95-101 (1999).
35. McIntosh SA, Going JJ, Soukop M, Purushotham AD, Cooke TG. Therapeutic implications of the sentinel lymph node in breast cancer. Lancet 354, 570 (1999).
36. Pargaonkar AS, Beissner RS, Snyder S, Speights VO Jr. Evaluation of immunohistochemistry and multiple-level sectioning in sentinel lymph nodes from patients with breast cancer. Arch. Pathol. Lab. Med. 127, 701-705 (2003).
37. Stitzenberg KB, Calvo BF, Iacocca MV et al. Cytokeratin immunohistochemical validation of the sentinel node hyphothesis in patients with breast cancer. Am. J. Clin. Pathol. 117, 729-737 (2002).
38. Weaver DL, Krag DN, Ashikaga T, Harlow SP, O'Connell M. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 88, 1099-1107 (2000).
39. Gillanders WE, Mikhitarian K, Hebert R et al. Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study. Ann. Surg. 239, 828-837 (2004).
40. Sakaguchi M, Virmani A, Dudak MW et al. Clinical relevance of reverse transcriptase-polymerase chain reaction for the detection of axillary lymph node metastases in breast cancer. Ann. Surg. Oncol. 10, 117-125 (2003).
41. Manzotti M, Dell'Orto P, Maisonneuve P, Zurrida S, Mazzarol G, Viale G. Reverse transcription-polymerase chain reaction assay for multiple mRNA markers in the detection of breast cancer metastases in sentinel lymph nodes. Int. J. Cancer 95, 307-312 (2001).
42. Cserni G, Burzykowski T, Vinh-Hung V et al. Axillary sentinel node and tumour-related factors associated with non-sentinel node involvement in breast cancer. Jpn. J. Clin. Oncol. 34, 519-524 (2004).
43. Calhoun KE, Hansen NM, Turner RR, Giuliano AE. Nonsentinel node metastases in breast cancer patients with isolated tumor cells in the sentinel node: implications for completion axillary node dissection. Am. J. Surg. 190, 588-591 (2005).
44. Schrenk P, Konstantiniuk P, Wolfl S et al. Prediction of non-sentinel lymph node status in breast cancer with a micrometastatic sentinel node. Br. J. Surg. 92, 707-713 (2005).
45. Fournier K, Schiller A, Perry RR, Laronga C. Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection. Ann. Surg. 239, 859-863 (2004).
46. Nos C, Harding-MacKean C, Freneaux P et al. Prediction of tumour involvement in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases. Br. J. Surg. 90, 1354-1360 (2003).
47. Yu JC, Hsu GC, Hsieh CB, Sheu LF, Chao TY. Prediction of metastasis to non-sentinel nodes by sentinel node status and primary tumor characteristics in primary breast cancer in Taiwan. World J. Surg. 29, 813-818 (2005).
48. van IV, Leidenius M, Krogerus L, von Smitten K. Predictive factors for the status of non-sentinel nodes in breast cancer patients with tumor positive sentinel nodes. Breast Cancer Res. Treat. 82, 39-45 (2003).
49. Hung WK, Chan MC, Mak KL et al. Non-sentinel lymph node matastases in breast cancer patients with metastatic sentinel nodes. ANZ J. Surg. 75, 27-31 (2005).
50. Fleming FJ, Kavanagh D, Crotty TB et al. Factors affecting metastases to non-sentinel lymph nodes in breast cancer. J. Clin. Pathol. 57, 73-76 (2004).
51. den Bakker MA, van Weeszenberg A, de Kanter AY et al. Non-sentinel lymph node involvement in patients with breast cancer and sentinel node micrometastasis; too early to abandon axillary clearance. J. Clin. Pathol. 55, 932-935 (2002).
52. Reynolds C, Mick R, Donohue JH et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J. Clin. Oncol. 17, 1720-1726 (1999).
53. Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. J. Med. 349, 546-553 (2003).
54. Schijven MP, Vingerhoets AJ, Rutten HJ et al. Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy. Eur. J. Surg. Oncol. 29, 341-350 (2003).
55. Haid A, Koberle-Wuhrer R, Knauer M et al. Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: a comparative evaluation. Breast Cancer Res. Treat. 73, 31-36 (2002).
56. Blanchard DK, Donohue JH, Reynolds C, Grant CS. Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch. Surg. 138, 482-487 (2003).
57. Burak WE, Hollenbeck ST, Zervos EE, Hock KL, Kemp LC, Young DC. Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am. J. Surg. 183, 23-27 (2002).
58. Golshan M, Martin WJ, Dowlatshahi K. Sentinel lymph node biopsy lowers the rate of lymphedema when compared with standard axillary lymph node dissection. Am. Surg. 69, 209-211 (2003).
59. Mansel RE, Fallowfield L, Kissin M et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J. Natl Cancer Inst. 98, 599-609 (2006).